Skip to content
  • Follow Us

CarboHyde

SUGAR IS LIFE

  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog
  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog

CarboHyde

SUGAR IS LIFE

  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog

Tag: biotech

Enzyme formulations and reaction mixtures for nucleic acid amplification

Jan 12, 2023Tamas SohajdaToday's cyclodextrinbiotech, biotechnology, nucleic acid, oligonucleotides

A fascinating patent application by Hologic, Inc. using CDs in enzyme formulations for nucleic acid amplification. The compositions are also useful in mitigating the inhibitory effect of sample extraction detergents.

See the full patent on PatentScope

Categories

  • carbohydrates
  • drug delivery
  • drug development
  • drug discovery
  • Egyéb kategória
  • news
  • Today's cyclodextrin

Archive

  • March 2023 (45)
  • February 2023 (34)
  • January 2023 (31)
  • December 2022 (23)
  • November 2022 (33)
  • October 2022 (38)
  • September 2022 (9)

Latest posts

  • Novoxyne and CarboHyde explore together cyclodextrin-based methods to reprogram somatic cells
  • Lysosomal cholesterol accumulation is commonly found in most peroxisomal disorders and reversed by 2-hydroxypropyl-β-cyclodextrin
  • Use of cyclodextrin to enhance solubility of substrates and increase enzymatic glycosylation reaction efficiency

Subscribe to our newsletter

alzheimers analytical chemistry anticancer atherosclerosis cancer research cancer treatment carbohyde cardiovascular chemistry cholesterol clinical trial covid19 cyclodextrin drug delivery formulation development gene therapy glycotime green chemistry infectious diseases monoclonal antibodies neurodegenerative diseases oncology research rare disease scientific advisory board synthesis

Developed by Shuttle Themes. Powered by WordPress.
  • Contact Us
  • LinkedIn
  • Twitter